Last reviewed · How we verify

NCT05651204

GABA Biomarkers in Dravet Syndrome

Recruiting now Last updated 14 December 2022
What this trial tests

trial testing GABA Blood Level in Dravet Syndrome in 36 participants. Currently enrolling.

Timeline
8 September 2022
Primary endpoint
8 September 2024
8 September 2027

Quick facts

Lead sponsorCook Children's Health Care System
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment36
Start date8 September 2022
Primary completion8 September 2024
Estimated completion8 September 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cook Children's Health Care System

Who can join

Under 18, any sex, with Dravet Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical responses, correlate them with the BOLD responses, and with the levels of GABA in their blood.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Dravet Syndrome

Currently open trials in the same condition.

Other Cook Children's Health Care System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05651204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing